← Peptide Database/5-Amino-1MQ
Metabolic Β· MitochondrialTier 3 β€” Animal + early human data

5-Amino-1MQ

5-amino-1-methylquinolinium Β· NNMT inhibitor

Small molecule NNMT inhibitor that reactivates dormant fat cells' metabolism. Early data shows fat mass reduction and muscle preservation without calorie restriction.

πŸ’‰ Oral🧊 Room temperature, protected from light and moisture

Want a personalised protocol?

Our AI generator builds a protocol tailored to your profile and goals.

Generate protocol β†’

Mechanism of Action

Inhibits nicotinamide N-methyltransferase (NNMT), increasing NAD+ levels and SAM in adipocytes. Shifts adipocyte metabolism from lipid storage to fat oxidation and thermogenesis.

Clinical Applications

  • βœ“Metabolic obesity (not dietary)
  • βœ“Fat loss resistant to diet/exercise
  • βœ“Metabolic syndrome
  • βœ“NAD+ pathway optimization

Dosing Protocol

Recommended Dosing

Oral capsule. 50–100 mg, 1–2x daily. Usually cycled 8–12 weeks on, 4–6 weeks off. Research compound β€” no established clinical protocols.

Safety & Contraindications

Possible Side Effects

  • ⚠Largely unstudied in humans
  • ⚠Potential digestive discomfort
  • ⚠Unknown long-term safety profile

Contraindications

  • βœ•Pregnancy
  • βœ•Liver disease (NAD+ pathway implications)
  • βœ•Unknown drug interactions

Combinations & Synergies

πŸ”— Semaglutidedual metabolic approach
πŸ”— MOTS-csynergistic mitochondrial + metabolic activation
#metabolic#NNMT#NAD+#fat-loss#obesity#research
← Back to database